Dear client,
Key Highlights
The following six topics will be discussed:
CDK 4/6 Inhibition: The Next Big Thing in ER+
Breast Cancer Impresses at SABCS 2012
CDK inhibitors have been on key opinion leaders’
radars recently as very promising agents, and the
results from the randomized Phase II trial
combining PD 0332991 (Pfizer) with Femara®
(letrozole,Novartis) did not disappoint.
Long-Term Adjuvant Therapy Is Improving
Outcomes in Breast Cancer and Is a Key
Theme at SABCS 2012
Adjuvant therapy continues to improve outcomes
in breast cancer. The HERA study showed that
two years of Herceptin (trastuzumab, Roche)
offered no additional benefit beyond what is
achieved with one year of Herceptin, and the
PHARE non-inferiority results showed that six
months of therapy was inconclusive but
potentially inferior to one year of Herceptin. So,
one year of adjuvant Herceptin will remain the
standard of care. In addition, The ATLAS data
showed that 10 years of tamoxifen was superior
to five years in ER+ patients.
New MOAs in Multiple Myeloma Shine at ASH
2012
New mechanisms of action are showing
promising activity in multiple myeloma.
Awareness of the changing myeloma landscape
will be critical for anyone thinking about initiating
new pivotal Phase III trials in this disease. ARRY520 (Array), elotuzumab (BMS, Abbvie, Ono) and
tabalumab (Eli Lilly) are highlighted.
New Options Emerging for Elderly Acute
Myeloid Leukemia (AML)
Presentations of positive Phase II data in elderly
AML patients at ASH 2012 suggest that two new
targeted agents - quizartinib (AC220, Ambit
Biosciences/Astellas) and volasertib (BI6727,
Boehringer Ingelheim) - may be efficacious in this
population and are poised to enter Phase III
development within the next year.
Not as BRIGHT as Hoped: Discordant Adverse
Events in BRIGHT versus StiL Causes Stir at
ASH 2012
Treanda (bendamustine, Teva, MundiPharma,
Symbio), in combination with Rituxan (rituxmab,
Roche), is vying for position in first-line Follicular
Lymphoma, where R-CHOP is the standard of
care. Data from the StiL study (presented at ASH
2009) suggested that R-Treanda is as effective as
and less toxic than R-CHOP. The follow-up
BRIGHT study was expected to produce more of
the same, but the results, while positive, were
disappointing with higher toxicity than expected.
Pomalidomide Shatters Any Black Clouds at
ASH
2012 Surrounding Its Future Use in Multiple
Myeloma
After a five-year dry-spell, the introduction of
Kyprolis (carfilzomib, Onyx) this year and the
impressive data for pomalidomide (Celgene) at
ASH 2012 portend to a new era in multiple
myeloma therapy.
You are receiving this email because your subscription to CancerMPact ®
entitles you to receive our complimentary oncology discussion piece, Oncology
Conference Insight. We invite you to review the latest issue and download it
directly from the Oncology Conference Insight website:
http://oci.khapps.com
This issue of Oncology Conference Insight highlights significant results
presented at the 2012 San Antonio Breast Cancer Symposium (SABCS),
which took place December 4 – 8 in San Antonio, Texas and the 2012
American Society of Hematology (ASH) Annual Meeting, which took place
December 8 – 11, 2012, in Atlanta, Georgia.
The discussion pieces available on this site summarize select presentations
from key conferences for CancerMPact® subscribers. The discussions are
intended to provide commercial organizations involved in the development and
marketing of new cancer therapeutics with topical articles and features relating
to oncology. Each edition will include news and comment about issues that
may impact an organization's development and commercialization strategies,
such as government policies and initiatives, pricing and reimbursement, and
reports about the latest research on specific cancers by competitors. Additional
information about forthcoming oncology meetings will also be included,
together with features about Kantar Health’s Oncology products and services.
Beyond the written pieces, at a custom offering level, Kantar Health’s Oncology
Conference Insight service lets you define the scope of surveillance at any
oncology conference. Then we report back to you, advising you of key
takeaways, changes to standards of care, competitor activities and messaging,
and new or emerging targets and compounds. The engagement delivers
professional analysis and opinions on the implications.
For more information on Oncology Conference Insight, send your contact
information to: jocelyn.cappel@kantarhealth.com.
Kantar Health
Dr. Stephanie Hawthorne, Director
Stephanie.Hawthorne@kantarhealth.com
Bill Bagwell, General Manager
Bill.Bagwell@kantarhealth.com